Who regulates GLP-1 and peptide advertising? Mostly the FDA. Under a 1971 agreement with the Federal Trade Commission, the FDA has primary charge of prescription drug advertising, and compounded semaglutide and tirzepatide are prescription drugs. The FTC leads on other ads, and its GLP-1 case so far targeted prices, fake reviews and billing.
Here is the argument of this piece. The phrase "FTC crackdown on peptide advertising" circulates in industry blogs and compliance webinars, and it gets the agency wrong. Almost every enforcement letter aimed at GLP-1 and peptide marketing since September 2025 was signed by the FDA, not the FTC. The FTC has acted, but on a different layer: what a telehealth company charges, how it handles reviews and cancellations, and what it does with patient data. That split is not an accident of politics. It follows a division of labour the two agencies wrote down in 1971, and it explains why the research peptide market, which labels its products "not for human consumption", has tried to sit outside the prescription drug rules altogether.
Nothing below is legal advice, and this page does not tell anyone how to market a product. It reports what the FDA, the FTC and the published letters say, with the primary document linked. For the legal status of each compound, the Ozemback peptide status tracker keeps a dated row per compound, and the BPC-157 reference page shows how one research peptide moved through FDA review. The earlier pieces on whether it is illegal to sell research peptides and on getting peptides through telehealth cover the criminal cases and the prescribing rules.
Does the FDA or the FTC regulate drug advertising?
Both, with a written split. The Memorandum of Understanding between the FTC and the FDA, signed by the FDA on 27 April 1971 and by the FTC on 14 May 1971, says the FTC has "primary responsibility" for the truth or falsity of all advertising, other than labelling, of foods, drugs, devices and cosmetics, with one exception. The FDA has primary responsibility for the truth or falsity of prescription drug advertising and primary jurisdiction over all labelling. The agreement allocates work between agencies. It does not shrink the FTC's statute: section 12 of the FTC Act, codified at 15 U.S.C. 52, still makes it unlawful to disseminate a false advertisement likely to induce the purchase of "food, drugs, devices, services, or cosmetics". That last word, services, is what lets the FTC look at a telehealth subscription even when the drug inside it is the FDA's business.
What has the FDA done about GLP-1 telehealth ads?
The FDA has sent letters in waves. On 9 September 2025 it announced "thousands of letters" to drug companies and about 100 cease-and-desist letters over deceptive ads, saying warning letters to drugmakers had fallen to one in 2023 and zero in 2024. On 3 March 2026 it announced 30 warning letters to telehealth companies selling compounded GLP-1s, for claims implying sameness with FDA-approved drugs and for putting the telehealth brand on the product as if the firm were the compounder. A law-firm summary from McDermott Will & Schulte, dated 30 June 2026, describes 25 more letters dated 16 June 2026, citing sections 502(a), 502(bb) and 301(a) of the FD&C Act and giving recipients 15 business days to respond.
| Date | Agency | Action | Target |
|---|---|---|---|
| 14 Jul 2025 | FTC | Complaint and proposed order, vote 3-0 | NextMed (GLP-1 weight-loss programmes) |
| 9 Sep 2025 | FDA | Thousands of letters, ~100 cease-and-desist | Drug advertisers |
| 3 Dec 2025 | FTC | Final order, $150,000 | NextMed and two principals |
| 3 Mar 2026 | FDA | 30 warning letters | Telehealth sellers of compounded GLP-1s |
| 16 Jun 2026 | FDA | 25 warning letters | Telehealth sellers of compounded GLP-1s |
| 29 Jul 2026 | FTC, Utah, California | Federal lawsuit, vote 2-0 | Hims & Hers (billing, cancellation, data sharing) |
| 24 Aug 2026 | FDA | 5 warning letters | Websites selling "research" GLP-1 peptides |
The FDA polices what an ad says about the drug. The FTC polices what the seller does to the buyer. A research peptide labelled "not for human consumption" was designed to fall between the two.
What has the FTC done about GLP-1 advertising?
The FTC's clearest GLP-1 case is NextMed. On 14 July 2025 the Commission voted 3-0 to issue a complaint against Southern Health Solutions, trading as NextMed, and two principals. It alleged memberships advertised at $138 or $188 a month that left out the cost of the drug, the lab work and the medical consultation, a claim that members lose 53 pounds and 23% of body weight on average without adequate support, before-and-after photos of people who were not customers, and gift cards offered to change negative reviews. The final order, announced on 3 December 2025, requires $150,000 for refunds and competent and reliable evidence for any typical-results claim. Its second telehealth case, filed on 29 July 2026 with Utah and California against Hims & Hers, is about billing, cancellation and data sharing, and the release does not mention GLP-1 drugs.
Who regulates research peptide advertising?
On paper, research peptides are not prescription drugs, which would put their advertising in the FTC's primary lane under the 1971 split. In practice the FDA has claimed them through labelling and intended use. On 24 August 2026 the FDA sent five warning letters to websites selling semaglutide, tirzepatide and retatrutide alongside other peptides, according to pharmaphorum on 2 September 2026. The sites labelled products "for research purposes only" or "not for human consumption", and a footnote in each letter said the evidence on the websites showed the products were intended to be drugs for human use. Once the FDA reads a website that way, the product is an unapproved drug and the website is evidence, which is why the "research use only" wording has not worked as a shield in the letters published so far.
The FTC's role in that market is mostly potential. Section 12 of the FTC Act reaches false advertisements for drugs and services by any seller, with no prescription requirement, and the FTC can seek orders and refunds where the FDA sends letters. A coalition of 13 groups led by the National Consumers League petitioned the FTC on 22 September 2025 to investigate telehealth ads for compounded GLP-1s, citing omitted risk information and claims of equivalence with approved drugs. As of 31 October 2026, a search of the FTC's press releases found no action against a seller of research peptides, which means the agency with the broader advertising statute has so far left that market to the agency with the labelling statute.
Is the FTC really staying out of it?
The strongest case against this reading is that the FTC is not absent, it is choosing different harms. The NextMed complaint did attack a drug-result claim, the average loss of 53 pounds, and the order now requires evidence for typical-results claims, which is the same discipline the FDA applies to drug efficacy. The Hims & Hers suit goes after recurring charges and data shared with advertising platforms, harms that an FDA warning letter about a label would never reach. On that view the agencies are not leaving a gap: the FDA covers what the product is, and the FTC covers what happens to the buyer's money and data. That is a fair description of the telehealth layer. It does not describe the research peptide layer, where no FTC case exists yet and the FDA's tool is a letter with a 15-day reply window.
What does the split mean for readers?
The practical point is about which promise you can check. Claims about the drug itself, sameness with Ozempic or Mounjaro, FDA approval, who compounded it, fall under the FDA, and the agency has now published 55 telehealth letters in 2026 that spell out which wordings it treats as misbranding. Claims about the service, monthly price, cancellation, reviews and results, fall under the FTC, which has one GLP-1 order and one pending telehealth lawsuit. Ozemback's view is that the "FTC crackdown" headline overstates one agency and understates the other, and that the research peptide market will stay a letter-by-letter fight until either agency brings a case that ends in an order rather than a request for a reply. The tracker will log that when it happens.
Sources
- Memorandum of Understanding between the Federal Trade Commission and the Food and Drug Administration, signed April and May 1971. www.ftc.gov
- 15 U.S.C. 52, Dissemination of false advertisements (section 12 of the FTC Act), Cornell Legal Information Institute. www.law.cornell.edu
- US Food and Drug Administration, FDA launches crackdown on deceptive drug advertising, press announcement, 9 September 2025. www.fda.gov
- US Food and Drug Administration, FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, press announcement, 3 March 2026. www.fda.gov
- McDermott Will & Schulte, FDA takes aim at misleading online claims for compounded GLP-1 drugs, 30 June 2026 (25 warning letters dated 16 June 2026). www.mcdermottlaw.com
- pharmaphorum, FDA issues warning letters to five unapproved GLP-1 websites, 2 September 2026 (letters dated 24 August 2026). pharmaphorum.com
- Federal Trade Commission, FTC takes action against telemedicine firm NextMed, press release, 14 July 2025. www.ftc.gov
- Federal Trade Commission, FTC approves final order against telehealth provider NextMed, press release, 3 December 2025. www.ftc.gov
- Federal Trade Commission, FTC and states act against Hims & Hers for deceptive and unlawful privacy practices, press release, 29 July 2026. www.ftc.gov
- National Consumers League, consumer, patient safety and public health groups petition the FTC, 23 September 2025 (petition dated 22 September 2025). nclnet.org
